Results 201 to 210 of about 1,059,597 (308)

Reduplication in Tok Pisin―Forms, Functions and Uses― [PDF]

open access: yes, 2012
Nose, Masahiko   +2 more
core  

Effect and Threshold of Endoscopic Findings for CRS Control Status and Long‐Term Outcome Prediction

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background EPOS 2020 defined chronic rhinosinusitis (CRS) disease control using patient symptoms and medication usage but endoscopic findings were considered optional. The effect of adding endoscopic features, an appropriate threshold, and their association with present or future symptom control have not been studied.
Steven Chun‐Kang Liao   +14 more
wiley   +1 more source

Nose [PDF]

open access: yesThe Journal of Laryngology, Rhinology, and Otology, 1908
openaire   +1 more source

Mechanisms of Mitochondrial Toxicity and Cytotoxicity Caused by Pseudomonas aeruginosa Pyocyanin in Human Nasal Epithelial Cells

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Pseudomonas aeruginosa is an opportunistic pathogen in cystic fibrosis‐related chronic rhinosinusitis (CF‐CRS) that produces phenazine metabolites pyocyanin and 1‐hydroxyphenazine (1‐HP), which may have detrimental effects on mitochondria, reactive oxygen species (ROS), Ca2+ signaling, and apoptosis.
Joel C. Thompson   +8 more
wiley   +1 more source

Nose [PDF]

open access: yesThe Journal of Laryngology, Rhinology, and Otology, 1909
openaire   +1 more source

Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT)

open access: yesInternational Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Loss of smell is a principal symptom of chronic rhinosinusitis with nasal polyps (CRSwNP), affecting health‐related quality of life and posing a safety hazard. Methods WAYPOINT (NCT04851964), a phase 3, multicenter trial in adults with uncontrolled CRSwNP, randomized patients 1:1 to receive tezepelumab 210 mg or placebo ...
Joaquim Mullol   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy